| - GRCh37:
- ChrMT:5782-13922
- GRCh38:
- ChrMT:5782-13922
| MT-ND4L, MT-ND5, MT-TC, MT-TD, MT-TR, MT-TS1, MT-TK, MT-TL2, MT-TS2, MT-TH, MT-TY, MT-ND4, MT-TG, MT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-ND3 | | Primary dilated cardiomyopathy, Macrocytic dyserythropoietic anemia | Likely pathogenic (Nov 4, 2014) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:5794-14876
- GRCh38:
- ChrMT:5794-14876
| MT-CYB, MT-ND3, MT-TL2, MT-TR, MT-TS1, MT-TS2, MT-TY, MT-ATP6, MT-ATP8, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-ND6, MT-TC, MT-TD, MT-CO1, MT-CO2, MT-CO3, MT-TE, MT-TK | | Primary dilated cardiomyopathy, Macrocytic dyserythropoietic anemia | Likely pathogenic (Nov 4, 2014) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:6468-15586
- GRCh38:
- ChrMT:6468-15586
| MT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-CYB, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MT-TD, MT-TE, MT-TG, MT-TH, MT-TK, MT-TL2, MT-TR, MT-TS1, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:7126-13988
- GRCh38:
- ChrMT:7126-13988
| MT-CO1, MT-CO2, MT-CO3, MT-ND3, MT-TD, MT-TG, MT-TL2, MT-TR, MT-TS1, MT-TS2, MT-ND4, MT-ND4L, MT-ND5, MT-TH, MT-TK, MT-ATP6, MT-ATP8 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8290-13040
- GRCh38:
- ChrMT:8290-13040
| MT-TR, MT-TS2, MT-ATP6, MT-ATP8, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-TK, MT-TL2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8350-13450
- GRCh38:
- ChrMT:8350-13450
| MT-TR, MT-TS2, MT-TK, MT-TL2, MT-ATP6, MT-ATP8, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH | | Pearson syndrome | Pathogenic (Jun 12, 2019) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8470-13446
- GRCh38:
- ChrMT:8470-13446
| MT-TG, MT-TH, MT-TL2, MT-TR, MT-TS2, MT-CO3, MT-ND3, MT-ND4, MT-ATP6, MT-ATP8, MT-ND4L, MT-ND5 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8480-13440
- GRCh38:
- ChrMT:8480-13440
| MT-ATP6, MT-ATP8, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TR, MT-TS2, MT-TG, MT-TH, MT-TL2 | | Pearson syndrome | Pathogenic (Jun 12, 2019) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8585-12965
- GRCh38:
- ChrMT:8585-12965
| MT-ATP6, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-TL2, MT-TR, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8815-13722
- GRCh38:
- ChrMT:8815-13722
| MT-ATP6, MT-CO3, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-TG, MT-TH, MT-TL2, MT-TR, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:8839-14895
- GRCh38:
- ChrMT:8839-14895
| MT-ATP6, MT-CO3, MT-CYB, MT-ND5, MT-ND6, MT-TE, MT-TG, MT-TS2, MT-ND3, MT-ND4, MT-ND4L, MT-TH, MT-TL2, MT-TR | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:10105-15066
- GRCh38:
- ChrMT:10105-15066
| MT-CYB, MT-ND3, MT-ND4, MT-TH, MT-TL2, MT-TR, MT-TS2, MT-ND4L, MT-ND5, MT-ND6, MT-TE | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:10947-15537
- GRCh38:
- ChrMT:10947-15537
| MT-TL2, MT-TS2, MT-CYB, MT-ND4, MT-ND5, MT-ND6, MT-TE, MT-TH | | Pearson syndrome | Pathogenic | criteria provided, single submitter |
| - GRCh37:
- ChrMT:11263-15374
- GRCh38:
- ChrMT:11263-15374
| MT-ND6, MT-TE, MT-TH, MT-CYB, MT-ND4, MT-ND5, MT-TL2, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:12114-14420
- GRCh38:
- ChrMT:12114-14420
| MT-ND4, MT-ND5, MT-ND6, MT-TH, MT-TL2, MT-TS2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:12271
- GRCh38:
- ChrMT:12271
| MT-TL2 | | Mitochondrial disease | Pathogenic (May 4, 2022) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12273
- GRCh38:
- ChrMT:12273
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12276
- GRCh38:
- ChrMT:12276
| MT-TL2 | | Mitochondrial disease | Likely pathogenic (Nov 30, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:12278
- GRCh38:
- ChrMT:12278
| MT-TL2 | | Mitochondrial disease, Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, multiple submitters, no conflicts |
| - GRCh37:
- ChrMT:12279
- GRCh38:
- ChrMT:12279
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12279
- GRCh38:
- ChrMT:12279
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12280
- GRCh38:
- ChrMT:12280
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12281
- GRCh38:
- ChrMT:12281
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12283
- GRCh38:
- ChrMT:12283
| MT-TL2 | | Mitochondrial disease | Pathogenic (May 22, 2017) | no assertion criteria provided |
| - GRCh37:
- ChrMT:12285
- GRCh38:
- ChrMT:12285
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12291
- GRCh38:
- ChrMT:12291
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12293
- GRCh38:
- ChrMT:12293
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12294
- GRCh38:
- ChrMT:12294
| MT-TL2 | | Mitochondrial disease | Uncertain significance (Oct 24, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:12295
- GRCh38:
- ChrMT:12295
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12297
- GRCh38:
- ChrMT:12297
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12302
- GRCh38:
- ChrMT:12302
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12302
- GRCh38:
- ChrMT:12302
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Mar 15, 2020) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12305-12306
- GRCh38:
- ChrMT:12305-12306
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12308
- GRCh38:
- ChrMT:12308
| MT-TL2 | | Mitochondrial disease | Benign (Jan 10, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:12311
- GRCh38:
- ChrMT:12311
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Benign (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12315
- GRCh38:
- ChrMT:12315
| MT-TL2 | | Mitochondrial disease | Likely pathogenic (Nov 30, 2022) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:12316
- GRCh38:
- ChrMT:12316
| MT-TL2 | | Mitochondrial disease | Uncertain significance (Feb 27, 2023) | reviewed by expert panel FDA Recognized Database |
| - GRCh37:
- ChrMT:12317
- GRCh38:
- ChrMT:12317
| MT-TL2 | | not specified | Uncertain significance (May 4, 2022) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12318
- GRCh38:
- ChrMT:12318
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Uncertain significance (Jul 12, 2019) | criteria provided, single submitter |
| - GRCh37:
- ChrMT:12320
- GRCh38:
- ChrMT:12320
| MT-TL2 | | Inborn mitochondrial myopathy | Pathogenic (Feb 1, 1997) | no assertion criteria provided |
| - GRCh37:
- ChrMT:12335
- GRCh38:
- ChrMT:12335
| MT-TL2 | | Juvenile myopathy, encephalopathy, lactic acidosis AND stroke | Likely pathogenic (Jul 12, 2019) | criteria provided, single submitter |